Sat, Mar 21, 2026 page5

• India gears up to produce cheap weight-loss jabs

  • AFP, MUMBAI, India
  • • 
    • 
    • 

  A deluge of weight-loss drugs is set to transform the global fight against obesity as India prepares to unleash low-cost generic versions of injections like Ozempic after a key patent expired yesterday.

  The move would dramatically widen access to treatments that have long been considered a luxury, especially in middle-income countries, where soaring demand has collided with steep prices.

  At clinics across Mumbai, doctors say they are already preparing for an influx in new patients.

  

  A photograph taken on Tuesday shows obesity doctor and consultant Swati Pradhan explaining the Mounjaro GLP-1 self-injectable device at her clinic in Mumbai, India.

  Photo: AFP

  More than 50 people walk into endocrinologist Nadeem Rais’ office every week seeking weight-loss injections.

  “We have around 70 to 80 patients on active treatment right now,” he said. “When generics come out and prices drop, that could go up to 200 easily.”

  His colleague Sunera Ghai agreed, saying that demand is “very high,” but many “probably aren’t taking it just because it is truly a luxury item at this point”.

  The breakthrough comes as patents on semaglutide — the active ingredient in drugs such as Ozempic and Wegovy — expired yesterday in India, the world’s largest supplier of generic medicines.

  By the end of the year, core patents on semaglutide would have expired in 10 countries that represent 48 percent of the global obesity burden, a study published earlier this month by researchers said.

  These include Brazil, China, South Africa, Turkey and Canada, the study said.

  For India’s drug giants, this marks the start of an aggressive new race. At least four major firms have already prepared generic semaglutide injections, regulatory filings and compliance documents viewed by AFP show.

  Some, including Zydus Lifesciences, have announced “Day 1” launches, suggesting generic versions might become available as soon as this weekend in India. Research firm Pharmarack estimates the Indian market would soon be flooded with options.

  “What we understand is, there will be more than 50 brands that will be launched in the market and there are more than 40 players who will be launching these drugs,” Pharmarack vice president Sheetal Sapale said.

  The timing aligns with India’s shifting health landscape.

  While India still accounts for one-third of the world’s undernutrition according to the WHO, rising incomes and urban lifestyles have pushed obesity rates sharply upward. Government data released in March last year shows 24 percent of women and 23 percent of men are overweight or obese in India.

  “Once a person starts earning money, he becomes more sedentary here,” bariatric surgeon Sanjay Borude said. “While in first-world countries, the more the money, they become more active and devote time for their health, this is reversed in India.”

  These flipped economics have worked well for big pharma players like Eli Lilly and Novo Nordisk who have been cashing in on the market.

  As of this year, India’s weight-loss drug sales have grown 10-fold in five years to US$153 million and are projected to soar to more than half a billion by 2030.

  However, using such drugs can cause side effects including nausea and gastrointestinal issues.

  Eli Lilly’s Mounjaro became the country’s top-selling drug by value last year, surpassing even common antibiotics. Still, high prices — often 15,000 to 22,000 rupees (US$160 to US$236) a month — limit access, says Swati Pradhan, who runs a weight-loss clinic in Mumbai. She expects patient numbers to rise once generics push treatment costs closer to 5,000 rupees a month.

  The global impact may prove even more profound. India supplies more than half of Africa’s generic medicines, and cheaper semaglutide could become a lifeline for countries where obesity is rising rapidly, but treatment remains unaffordable.

  “Lower-cost semaglutide could significantly expand access to effective treatment particularly in middle-income countries where price has been a major barrier,” World Obesity Federation president Simon Barquera said. “Generic products are an important step in breaking the access barrier, now that the scientific one has been overcome.”

  Indian firms would be a key driving force, with Dr Reddy’s Laboratories aiming to launch its version of semaglutide in Canada by May.

  For patients like 46-year-old Sukant Mangal, who lost nearly 30 pounds (13.6kg) in eight months, wider access could not come soon enough. Many he knows simply abandoned treatment midway when they realized they would have to spend 20,000 rupees a month for seven to eight months.

  “Had it been cheaper, [it] would’ve been much easier to have it,” he said.
• Most Popular

  • 1

    First person arrested as Danjiang Bridge opens

  • 2

    TSMC shares stumble on report, but losses minor

  • 3

    Navy needs 12 subs for modern fleet: CSBC head

  • 4

    Police identify man who engaged in indecency at park

  • 5

    HIMARS to be deployed to islands